With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious. AstraZeneca had already been quick to consider ...

SGLT-2 inhibitors, compared with DPP-4 inhibitors, were associated with a lower risk for liver cirrhosis among patients with type 2 diabetes. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors, ...

“Our data suggest SGLT2 inhibition as a safe strategy to prevent kidney stone recurrence in patients with kidney stones ,” Dr Fuster’s team concluded. Other study findings indicate the empagliflozin ...

Monotherapy with SGLT2 inhibitors or GLP-1RAs is associated with cardiorenal benefits ... Please see the original reference for a full list of authors’ disclosures.

The use of SGLT2 inhibitors was associated with reduced risks for cardiovascular and renal complications among patients with both systemic lupus erythematosus and type 2 diabetes, compared with DPP4 ...

If you continue to have this issue please contact [email protected]. Starting SGLT2 inhibitors led to a lower risk of eGFR decline or incident kidney failure. SGLT2 inhibitors were also ...

Monotherapy with SGLT2 inhibitors or GLP-1RAs is associated with ... Please see the original reference for a full list of authors’ disclosures.

They added that “it seems very likely that SGLT2 inhibitors will also result in ... Please see the original reference for a full list of disclosures.

SGLT2 inhibitors are a new family of agents, which occlude the path of SGLT2 glucose reabsorption and cause glucosuria. Efficacy of SGLT2 inhibitors includes reduction of HbA1c, fasting and ...

A RETROSPECTIVE cohort study has revealed that the use of SGLT2 inhibitors significantly improves kidney health in a diverse group of Asian adults with Type 2 diabetes. The research, conducted by ...

A recent study conducted across public hospitals in Hong Kong highlighted the superiority of sodium-glucose cotransporter 2 (SGLT2) inhibitors over dipeptidyl peptidase-4 (DPP-4) inhibitors in ...